Super Bowl LX becomes the GLP-1 Super Bowl

Four companies selling or prescribing GLP-1 weight-loss treatments bought advertising around Super Bowl LX on February 8, 2026, turning the NFL's biggest broadcast into what one marketing professor called "the GLP-1 Super Bowl" ^[5]. Novo Nordisk, Eli Lilly, telehealth company Ro and Hims & Hers each pitched a version of weight-loss care to an audience Nielsen projected at around 130 million people ^[1].

Novo Nordisk ran its first Super Bowl ad, a 90-second spot built around the new Wegovy pill ^[1][2]. Comedian Kenan Thompson announces the pill alongside DJ Khaled, John C. Reilly, Danielle Brooks, Ana Gasteyer and Danny Trejo, who joke that they would happily take a pill that helped them parallel park, become a pro wrestler or rescue more kittens ^[1][2]. The message is that people with obesity should not feel embarrassed about using medication. "The goal is to generate as much awareness [for the pill] as we can," Novo marketing senior vice president Edward Cinca told Adweek ^[2].

Ro made its Super Bowl debut with a 30-second in-game spot fronted by Serena Williams, part of a "Healthier on Ro" campaign across TV, paid social and outdoor advertising ^[2][3]. Co-founder Saman Rahmanian said the company enlisted Williams to "dispel the myth that taking weight loss medications is cheating" ^[2]. Hims & Hers returned for a second year with a fourth-quarter ad voiced by Common under the line "Rich People Live Longer," arguing that expensive treatments are reserved for the wealthy — without naming the GLP-1 drugs it sells, a change from its 2025 spot ^[1][2]. Eli Lilly took a different route, advertising Zepbound (tirzepatide) during NBC's pre-game show and inside the game on Peacock, where NBC has said slots cost roughly half the broadcast price ^[1]. Ad tracker iSpot lists a Zepbound Super Bowl 2026 spot called "Watch This" ^[6].

The price of admission

Sources differ on exactly what the airtime cost. Adweek reported spots ran up to $10 million for 30 seconds and that GLP-1 brands each spent upwards of $10 million ^[1][2]. NBCUniversal's Peter Lazarus said spots averaged about $8 million, with some exceeding $10 million for the first time ^[5]. Times of San Diego reported the $10 million threshold was surpassed for the first time ^[3].

The spending reflects a business shift. Novo's Wegovy pill — same active ingredient, semaglutide, as injectable Wegovy and Ozempic — was approved by the FDA in December and sells on the company's cash-pay website at a starter price of $149 ^[1][2]. Lilly's oral weight-loss drug is expected to be approved in April ^[1]. Adweek, citing Grand View Research, reported that 12% of American adults now use a GLP-1 and that US patients spent $40 billion on these drugs in 2024, a figure projected to triple by 2030 ^[2]. Media intelligence firm Guideline AI told Reuters that overall pharmaceutical ad spending last year could have fallen as much as 5% without the GLP-1 category ^[1].

The week also showed the limits of cheap copies. Hims & Hers launched a compounded semaglutide pill at a starting price of $49 on Thursday, February 5, then reversed course on Saturday after legal threats from Novo Nordisk and warnings from the FDA about companies marketing copycat drugs ^[1][2].

Why it matters for patients

A 30-second ad cannot carry the information needed to judge whether a drug fits a particular person. These spots focus on awareness and stigma, not on side effects, eligibility, how long treatment lasts, or what happens to weight after stopping — none of which the sources describe as part of the creative.

Price claims also deserve a close read. The $149 figure for the Wegovy pill is described as a starter price on a cash-pay direct-to-consumer site ^[1] and as an average monthly cost ^[2]; the sources do not say what it costs after the starter period or how insurance coverage applies. The Hims episode shows that a much cheaper compounded version can appear and disappear within days under legal pressure ^[1][2].

What happens next

Lilly's oral weight-loss drug is expected to be approved in April ^[1]. Novo's Wegovy pill had tracked over 26,000 prescriptions as of late January ^[1]. Whether the FDA takes further action against companies marketing compounded copies is not yet resolved in these sources ^[1].